GERON CORP Class of Warrant or Right, Outstanding
GERON CORP (GERN) had Class of Warrant or Right, Outstanding of 29.29 million shares as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-03-02
- 2025-12-31: Class of Warrant or Right, Outstanding 29.29M shares.
- 2024-12-31: Class of Warrant or Right, Outstanding 60.84M shares.
- 2023-12-31: Class of Warrant or Right, Outstanding 53.90M shares.
- 2022-12-31: Class of Warrant or Right, Outstanding 106.25M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2025-12-31 | 29.29M shares 10-K · filed 2026-03-02 |
| 2024-12-31 | 60.84M shares 10-K · filed 2025-02-27 |
| 2023-12-31 | 53.90M shares 10-K · filed 2024-02-28 |
| 2022-12-31 | 106.25M shares 10-K · filed 2023-03-16 |
| 2021-12-31 | 64.11M shares 10-K · filed 2022-03-10 |
| 2020-12-31 | 66.55M shares 10-K · filed 2021-03-11 |
| 2019-12-31 | 537.89K shares 10-K · filed 2020-03-12 |
| 2018-12-31 | 537.89K shares 10-K · filed 2019-03-07 |
| 2017-12-31 | 537.89K shares 10-K · filed 2018-03-16 |
| 2016-12-31 | 537.89K shares 10-K · filed 2017-03-01 |
| 2015-12-31 | 537.89K shares 10-K · filed 2016-03-10 |
| 2014-12-31 | 1.01M shares 10-K · filed 2015-03-11 |
| 2013-12-31 | 1.62M shares 10-K · filed 2014-03-17 |
| 2012-12-31 | 1.62M shares 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |